Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by the FDA label: warfarin sodium can cause major or fatal bleeding, bleeding risk is more likely within the first month, and risk mitigation includes INR monitoring and patient counseling to report bleeding.
Category Scores
Accurate Statements
Warfarin sodium can cause major or fatal bleeding.
Boxed Warning: “Warfarin sodium can cause major or fatal bleeding.”
Bleeding risk is increased within the first month.
Warnings and Precautions (5.1): “Bleeding is more likely to occur within the first month.”
Risk mitigation includes monitoring (INR).
Warnings and Precautions (5.1): “Perform regular monitoring of INR in all treated patients.” and 2.4: narrow therapeutic range requiring careful INR monitoring.
Risk mitigation includes patient counseling to report bleeding.
Warnings and Precautions (5.1): “Instruct patients about prevention measures… and to report signs and symptoms of bleeding”; Patient Counseling Information (17).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsafe or contradicted claims were made; the statements reflect label-supported bleeding risk and its labeled mitigation (INR monitoring and patient counseling).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement